lutetium has been researched along with Adenocarcinoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Tagawa, ST | 1 |
| Baum, RP; Klette, I; Kulkarni, HR; Osterkamp, F; Reineke, U; Schuchardt, C; Singh, A; Smerling, C; Wiessalla, S | 1 |
| D'Alessandria, C; Eiber, M; Gschwend, JE; Heck, MM; Janssen, F; Maurer, T; Rauscher, I; Retz, M; Scheidhauer, K; Schottelius, M; Schwaiger, M; Storz, E; Tauber, R; Wester, HJ | 1 |
| Eberwein, DJ; Ingram, AC; Knick, VC; Murray, DM; Ryan, CH; Stimmel, JB; Thurmond, LM; Witherspoon, SM | 1 |
| Anderson, TL; Atcher, RW; Nayak, TK; Norenberg, JP; Prossnitz, ER; Stabin, MG | 1 |
| Alvarez, RD; Grizzle, WE; Khazaeli, MB; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J; Wheeler, RH | 1 |
| Carrasquillo, JA; Chung, Y; Curt, G; Feuerstein, I; Milenic, DE; Mulligan, T; Paik, C; Perentesis, P; Reynolds, J; Schlom, J | 1 |
| Alvarez, RD; Austin, JM; Grizzle, WE; Khazaeli, MB; Kilgore, LC; Lin, CY; LoBuglio, AF; Macey, DJ; Meredith, RF; Partridge, EE; Schlom, J | 1 |
| Brechbiel, MW; Chappell, LL; Dadachova, E; Garmestani, K; Ma, D; Milenic, DE; Schlom, J; Yordanov, A | 1 |
3 trial(s) available for lutetium and Adenocarcinoma
| Article | Year |
|---|---|
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Topics: Adenocarcinoma; Aged; Antibodies, Neoplasm; Dose-Response Relationship, Radiation; Female; Humans; Lutetium; Middle Aged; Ovarian Neoplasms; Radioimmunodetection; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon | 1996 |
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage | 1995 |
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Intraperitoneal; Interferon Type I; Lutetium; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Recombinant Proteins; Treatment Outcome | 2001 |
6 other study(ies) available for lutetium and Adenocarcinoma
| Article | Year |
|---|---|
PSMA-targeted therapy in prostate cancer.
Topics: Adenocarcinoma; Antibodies, Bispecific; Antibodies, Neoplasm; Antigens, Surface; Biomarkers, Tumor; Clinical Trials as Topic; Dipeptides; Docetaxel; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lutetium; Male; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Randomized Controlled Trials as Topic | 2021 |
Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Drug Design; Female; Humans; Injections, Intravenous; Kidney; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Neurotensin; Retrospective Studies; Salvage Therapy; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Topics: Adenocarcinoma; Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2016 |
Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Survival; Chromium; Colonic Neoplasms; Epithelial Cell Adhesion Molecule; Female; G2 Phase; Humans; In Vitro Techniques; Lutetium; Male; Mice; Mice, Nude; Mitosis; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Alpha Particles; Beta Particles; Bismuth; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Delivery Systems; Humans; Lutetium; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome | 2007 |
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Topics: Adenocarcinoma; Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Whole-Body Counting; Xenograft Model Antitumor Assays | 2002 |